ACAA

10.0500.00%
US

Ulrik Schulze

Independent Director

Dr. Ulrik Schulze is Independent Director of Averin Capital Acquisition Corp. from February 19, 2026. Dr. Ulrik Schulze is Director of BioVersys AG from June 27, 2025. He is Chairman and Managing Director of Sanrigen GmbH, a life science advisory and a Senior Advisor at The Boston Consulting Group (BCG). Until recently, he was a Managing Director and Senior Partner at BCG where he held several global leadership roles, most recently leading BCG’s global Biopharma Sector and member of the global Health Care Leadership Team. Before that he led BCG’s global Biopharma R&D business. He serves as Non -Executive Director of Biograil Aps and a Non -Executive Director of Indivi AG. He also held several leadership positions in BCG Switzerland, including Head of Business Development, People Chair and Head of the Health Care business. Dr. Schulze has more than 30 years of consulting experience in the life science and private equity industries. From October 2021 to November 2023, he served as Chairman of ReproNovo SA, a privately held Swiss biotechnology company. He has extensive experience working with boards, CEOs and senior executives of large pharmaceutical companies and biotech companies in Europe, the US and Asia. His work has focused on strategy development, capital markets, M&A, post-merger integration and organizational transformations across the value chain. He is a globally recognized thought-leader on R&D strategy and productivity and has supported launch of several blockbusters. In 2022, he co-authored “The case for a subscription model to tackle antimicrobial resistance”. He is also a co-founder of ReproNovo, a biotech company in reproductive medicine, that has raised significant Series A funding. He holds an M.Sc. in Chemical Engineering and a Ph.D. in Biotechnology, both from the Technical University of Denmark.

Positions